Tim Benepal

Author Correction: Integrated genomics point to immune vulnerabilities in pleural mesothelioma

Anca Năstase, Amit Kumar Mandal, Shir Kiong Lu, Hima Anbunathan et autres

In the Results section, under subheading ‘High level of VISTA is frequent in epithelioid mesothelioma and its expression level correlates with Hedgehog and immune pathway components’,

gb, ca, us (code pays fourni par la source)

A quality improvement study aiming to quantify anti-emetic steroid usage and documentation of consent and adverse effects in lung cancer patients

Nabeel Naban, Abu Taher, Jennifer Gunberg Ross, Talia Shively et autres

Integrated genomics point to immune vulnerabilities in pleural mesothelioma

Anca Năstase, Amit Kumar Mandal, Shir Kiong Lu, Hima Anbunathan et autres

Pleural mesothelioma is an aggressive malignancy with limited effective therapies. In order to identify therapeutic targets, we integrated SNP genotyping, sequencing and transcriptomics from tumours and low-passage patient-derived cells. Previously unrecognised deletions of SUFU locus (10q24.32), observed in 21% of 118 tumours, …

gb, ca, us (code pays fourni par la source)

Corrigendum to Cancer, mental health and end of life simulation (CAMhELS): A novel effectiveness evaluation

Andrew Michael Fernando, Tim Benepal, Kiruthikah Thillai, Ollie Minton et autres

gb, us (code pays fourni par la source)

Integrated genomics identify novel immunotherapy targets for malignant mesothelioma

Anca Năstase, Amit Kumar Mandal, Shir Kiong Lu, Hima Anbunathan et autres

Abstract Background Malignant pleural mesothelioma (MPM) is an aggressive malignancy with limited effective therapies. Methods In order to identify therapeutic targets, we integrated SNP genotyping, sequencing and transcriptomics from tumours and low-passage patient-derived cells. Results Previously unrecognised losses of SUFU locus (10q24.32), …

gb, ca (code pays fourni par la source)

The challenges of complex molecular testing pathways and the benefits of in-house testing

Jeffrey A. Ross, Michael Foley, Tim Benepal, Jarva Chow et autres

The use of atezolizumab combination therapy in the EGFR+ metastatic non-squamous NSCLC setting: practical guidance based on early clinical experience

T. Geldart, Petru Belitei, Tim Benepal, Anita A. Mehta et autres

Cancer, mental health and end life simulation (CAMhELS): A novel effectiveness evaluation

Andrew Michael Fernando, Tim Benepal, Kiruthikah Thillai, Ollie Minton et autres

gb (code pays fourni par la source)

Second-line chemotherapy for locally advanced or metastatic small cell lung cancer

Adrian Draper, Yee‐Ean Ong, Stephen J Milan, Steve Powell et autres

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The objective of this systematic review is to explore the benefits of second‐line chemotherapy in patients with resistant (a relapse within three months of first treatment) or relapsed …

gb (code pays fourni par la source)

82: Mutational testing in lung adenocarcinoma patients – Are we testing everyone we should be?

R.C. Jones, Tim Benepal

55: Somatic BAP1 and NF2 mutations in pleural malignant mesothelioma and their correlation with clinical phenotype

Spyridon Gennatas, Shan Lu, Hima Anbunathan, Sanjay Popat et autres

Complete resolution of refractory hypercalcemia following pneumonectomy in squamous cell carcinoma of the lung

Doraid Alrifai, Styliani Germanou, Brendan Tinwell, Edward J. Cetti et autres

Patients with squamous cell carcinoma of the lung, amenable to complete resection, can suffer symptomatic humoral hypercalcemia of malignancy (HHM). This can compromise performance status and, ultimately, the candidacy for resection. Two cases highlighting initial pharmacological attempts at pre-operative correction of both …

gb (code pays fourni par la source)